PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Minocycline - Non-acne dermatological indications

PAD Profile : Minocycline - Non-acne dermatological indications

Keywords :
Antibiotic, Antibacterial, folliculitis decalvans, rosacea, pyoderma gangrenosum, bullous pemphigoid, vitiligo,
Brand Names Include :
Acnamino, Minocin MR, Aknemin

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Modified release tablets
  • Tablets
Important Information :
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
R
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Type
Document
Review Date
Information
Minocycline for non-acne dermatology indications - February 2019.pdf

Committee Recommendations

Date
Committee Name
Narrative
05 June 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey and North West Sussex Area Prescribing Committee recommends minocycline for non-acne related dermatological indications, noting that there is limited supporting evidence data available and there are concerns about serious side effects for minocycline. (February 2019 APC).

Minocycline for non-acne related dermatology indications will be considered RED on the traffic light system.

Associated BNF Codes

05. Infections
05.01.03. Tetracyclines
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More